fda shortage tirzepatide news confirms is still over, gives compounders a grace period Tirzepatide is NO longer in – Mounjaro and Zepbound Are No – FDA Removes Tirzepatide from Shortage

Giacco A, Delli Paoli G, Senese R, Cioffi F, Silvestri E, Moreno M, et al

GLP-1 drugs as a class have shown mixed results in heart failure populations

Semaglutide, other obesity drugs show potential to treat nondiabetic stroke GLP-1 receptor agonists such as semaglutide may be able to help reduce the risk of ischemic stroke in patients without diabetes, according to a new meta-analysis of preclinical studies published in Stroke .[1] These drugs have been linked to several key improvements in the cardiovascular health of patients with type 2 diabetes

The health benefits for infants, reduced infections, improved immune function, potential long-term metabolic benefits, are well established

This approach shapes how we select our team, invest in technology, structure our treatment plans, and serve our community across the Dallas-Fort Worth area

The medication itself is fully regulated and approved for use